The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2015-03-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-015-3331-5PMID 25762476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin inhibits histone H2B monoubiquitination and downstream gene transcription in human breast cancer cells

  2014cited by this paper
• The effect of metformin on breast cancer outcomes in patients with type 2 diabetes

  2014influential reference
• Metformin Induces Apoptosis and Cell Cycle Arrest Mediated by Oxidative Stress, AMPK and FOXO3a in MCF-7 Breast Cancer Cells

  2014cited by this paper
• IGF-1 Regulates Cyr61 Induced Breast Cancer Cell Proliferation and Invasion

  2014cited by this paper
• Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival.

  2013cited by this paper
• Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes

  2013cited by this paper
• Systematic review and meta‐analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer

  2013cited by this paper
• Associations of insulin‐like growth factor and insulin‐like growth factor binding protein‐3 with mortality in women with breast cancer

  2013cited by this paper
• Association Between Metformin Therapy and Mortality After Breast Cancer

  2013influential reference
• Diabetes, metformin, and breast cancer in postmenopausal women.

  2012cited by this paper
• Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes

  2012cited by this paper
• Metformin and breast cancer risk: a meta-analysis and critical literature review

  2012cited by this paper
• Mortality After Incident Cancer in People With and Without Type 2 Diabetes

  2012cited by this paper
• Metformin and the Risk of Cancer

  2012cited by this paper
• Cellular and molecular mechanisms of metformin: an overview.

  2012cited by this paper
• Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up

  2012cited by this paper
• Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

  2012influential reference
• MortalityAfter Incident Cancer in People With andWithout Type 2 Diabetes Impact of metformin on survival

  2012cited by this paper
• Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer

  2012influential reference
• The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus

  2012cited by this paper
• Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

  2011cited by this paper
• Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth

  2011cited by this paper
• Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.

  2011cited by this paper
• Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case–Control Study in Denmark

  2010cited by this paper
• Adaptation and validation of the Charlson Index for Read/OXMIS coded databases

  2010cited by this paper
• Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

  2009cited by this paper
• Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

  2007cited by this paper
• Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis

  2007cited by this paper
• Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

  2006cited by this paper
• Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

  2006cited by this paper
• Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines.

  2005cited by this paper
• Diabetes mellitus and breast cancer.

  2005cited by this paper
• Essential Medical Statistics

  2003cited by this paper
• Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.

  1991cited by this paper

• Diabetes Driven Oncogenesis and Anticancer Potential of Repurposed Antidiabetic Drug: A Systemic Review

  2024cites this paper
• Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link

  2024cites this paper
• EVOLUTION OF METFORMIN IN BREAST CANCER THERAPY IN LAST TWO DECADES: A REVIEW.

  2024cites this paper
• Associations between Diabetes Mellitus and Selected Cancers

  2024cites this paper
• Viability Profiles of Normal and Cancer Bladder Cells With Metformin, Nitrate and Adenosine Monophosphate-Activated Protein Kinase Inhibitor

  2023cites this paper
• Bioinformatics and network biology approach to identifying type 2 diabetes genes and pathways that influence the progression of breast cancer

  2023cites this paper
• Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies

  2022cites this paper
• Influence of type 2 diabetes mellitus on mortality in women with breast cancer: A matched case-control study.

  2022cites this paper
• Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs

  2021cites this paper
• Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials

  2021cites this paper
• Impact of insulin use on outcomes of diabetic breast cancer patients: a systematic review and meta-analysis.

  2021cites this paper
• Diabetes and Breast Cancer

  2021cites this paper
• Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes

  2021cites this paper
• Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status

  2020cites this paper
• Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study

  2020cites this paper
• Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer.

  2020cites this paper
• The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose–response of randomized clinical trials

  2019cites this paper
• The role of metformin and statins in ovarian and breast cancer in women with type 2 diabetes

  2019influential citation
• The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes

  2018cites this paper
• Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/&bgr;‐catenin/c‐Myc signaling pathway in human gastric cancer cell

  2018cites this paper
• Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis

  2018cites this paper
• Metformin-induced anticancer activities: recent insights

  2017cites this paper
• The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies

  2017cites this paper
• Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells.

  2017cites this paper
• Metformin to Treat Cancer: Misstep in Translational Research from Observational Studies.

  2017cites this paper
• The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysis

  2017cites this paper
• Diabetes drugs and the incidence of solid cancers: a survey of the current evidence

  2017cites this paper
• Type 2 diabetes, insulin treatment and prognosis of breast cancer

  2017cites this paper
• Insulin use, adipokine profiles and breast cancer prognosis

  2017cites this paper
• Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?

  2017cites this paper
• Determinants of mortality in patients with type 2 diabetes: a review

  2016cites this paper
• Pharmacodynamics and Systems Pharmacology Approaches to Repurposing Drugs in the Wake of Global Health Burden

  2016cites this paper
• Metformin use and survival from lung cancer: A population-based cohort study.

  2016cites this paper
• Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs

  2016cites this paper
• Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer.

  2016cites this paper
• Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress

  2015cites this paper
• Obesity and cancer, a case for insulin signaling

  2015cites this paper
• Expanding the therapeutic spectrum of metformin: from diabetes to cancer

  2015cites this paper
• Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?

  2015cites this paper